- Potential non-surgical treatment for residual lesions of involuted infantile hemangiomas, involving the administration of a drug containing at least one bile acid or its salt
- Avoids the dangers associated with common treatment methods involving surgery and anesthesia, including scarring, nerve damage, infection, bleeding, and tissue necrosis
- Projected to be more financially accessible to patients and less invasive when compared to currently available treatment methods
OVERVIEW
Georgetown University researchers have discovered a potential non-surgical treatment for residual lesions of involuted infantile hemangiomas. This pharmacological treatment involves the administration of at least one bile acid (such as deoxycholic acid) or its salt, and shows promise to be more financially accessible and safer for patients when compared to other current treatment methods.
BACKGROUND
Vascular anomalies encompass a variety of rare and often complex tumors, malformations, and vascular birthmark-producing syndromes that are produced by some localized defect in one or more elements of the vasculature (i.e., arteries, veins, capillaries and lymphatics). If left untreated, such anomalies can lead to permanent conditions such as telangiectasia, anetoderma, and excess fibrofatty tissue—all of which can cause significant cosmetic or functional concerns. Current treatment methods are expensive and involve risks related to surgery and anesthesia. Therefore, there is an acute need for a novel therapeutic approach to treat vascular anomalies, such as fibrofatty residua of involuted infantile hemangiomas, that is financially accessible and safer than current treatment options.
Benefit
Use of bile acids and their salts to treat residual lesions of vascular anomalies
Ability to prevent disease progression to more severe and permanent conditions
More cost-effective and non-invasive compared to currently available treatment options
Avoids the risks associated with current treatments that involve surgery and anesthesia
Market Application
A novel potential treatment method for vascular anomalies such as involuting infantile hemangiomas, involuted infantile hemangiomas, congenital hemangiomas, kaposiform hemangioendotheliomas (KHE), tufted angiomas, lymphatic malformations, and other vascular anomalies that comprise a residual lesion.
Publications
Intralesional Deoxycholic Acid Treatment for Fibrofatty Residua of Involuted Infantile Hemangiomas (DOI: 10.1001/jamadermatol.2018.0617) (link: https://jamanetwork.com/journals/jamadermatology/article-abstract/2679048)
Our mission is to advance GU’s innovations through strategic alliances and new venture creation, to facilitate the translation of research breakthroughs into tangible solutions, and to cultivate a dynamic and inclusive environment for entrepreneurship. We advance this mission in support of the GU community and for the benefit of society.
Create your free account to connect with Georgetown University and thousands of other innovative organizations and professionals worldwide
Send a request for information
to Georgetown University
Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.
Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support
